ZEGALOGUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEGALOGUE (ZEGALOGUE).
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist that increases blood glucose by activating hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis.
| Metabolism | Dasiglucagon is metabolized via proteolytic degradation into smaller peptides and amino acids; CYP enzymes are not involved. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%) and minor hepatic metabolism with biliary/fecal elimination (10-15%). |
| Half-life | Terminal elimination half-life is 5-7 hours in healthy adults; in hepatic impairment, half-life may be prolonged up to 12 hours, requiring dose adjustment. |
| Protein binding | Approximately 85% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.8 L/kg, indicating moderate tissue distribution with concentrations in tissues approximately 1.5 times plasma. |
| Bioavailability | Oral: 40-50% (due to first-pass metabolism); Intramuscular: 90-100%. |
| Onset of Action | Intravenous: Within 1-2 minutes; Intramuscular: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | Intravenous: 4-6 hours; Intramuscular: 6-8 hours; Oral: 4-6 hours. Duration may be extended in renal impairment. |
| Molecular Weight | 470.5 |
Initial dose: 2 mg subcutaneously once daily for 2 weeks, then increase to 7 mg subcutaneously once daily. Dose may be increased to 12 mg subcutaneously once daily after 4 weeks if additional glycemic control is needed.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m2). Not recommended for use in patients with end-stage renal disease (eGFR <15 mL/min/1.73 m2) due to lack of data. |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended in these patients. |
| Pediatric use | Not indicated for pediatric patients; safety and efficacy in patients <18 years have not been established. |
| Geriatric use | No specific dose adjustment required based on age alone. However, dosing should be cautious due to potential for decreased renal function or comorbidities; monitor renal function and volume status. |
| 1st trimester | No adequate studies in pregnant women. Animal studies show fetal risk. Use only if potential benefit justifies potential risk. |
| 2nd trimester | No adequate studies in pregnant women. Animal studies show fetal risk. Use only if potential benefit justifies potential risk. |
| 3rd trimester | May cause premature closure of ductus arteriosus in fetus; avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for ZEGALOGUE (ZEGALOGUE).
| Placental transfer | Crosses placenta (based on animal studies and molecular weight <500 Da). |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ZEGALOGUE or any componentThird trimester of pregnancyLactation
| Precautions | Risk of serious hypersensitivity reactions including anaphylaxis, May cause nausea and vomiting, Risk of hypoglycemia if used in patients with insulinoma or glucagonoma, May increase blood pressure and heart rate |
| Food/Dietary | No specific food interactions. After recovery, administer oral carbohydrates to replenish liver glycogen and prevent recurrent hypoglycemia. Avoid alcohol as it may impair glucose recovery. |
| Clinical Pearls |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Zegalogue (dasiglucagon) is a glucagon analog for severe hypoglycemia. No human pregnancy data; animal studies show no teratogenicity at exposures up to 40 times human dose. Risk cannot be excluded; use only if benefit outweighs risk. Fetal risks: potential for maternal hypoglycemia-induced fetal distress if not treated. |
| Fetal Monitoring | Monitor maternal blood glucose and response to treatment. Fetal monitoring not required for acute use; in pregnant patients, consider fetal heart rate monitoring if maternal hypoglycemia severe. |
| Fertility Effects | No human fertility data. Animal studies: no effects on fertility or reproductive performance in rats at doses up to 40 times human exposure. |
| ZEGALOGUE (dasiglucagon) is a soluble glucagon analog indicated for severe hypoglycemia. It is stable in liquid form, avoiding reconstitution. Onset of action is 10-15 minutes, with blood glucose rise similar to native glucagon. Note that it can cause nausea and vomiting; if patient is unconscious, place in recovery position. Do not use if patient has pheochromocytoma, insulinoma, or known hypersensitivity. Store at room temperature. |
| Patient Advice | Use only for severe hypoglycemia when patient is unable to take carbs orally or is unconscious. · Inject into buttock, thigh, or abdomen; no need to mix or reconstitute. · After injection, call emergency services immediately. · Administer supplemental carbs (if conscious and can swallow) after blood glucose responds. · Common side effects: nausea, vomiting, headache, injection site pain. · Store at controlled room temperature (20-25°C); do not freeze. |